Clinical Oncology Education

Breakthrough in Oncology: Combining Radiopharmaceuticals and CAR T-Cell Therapy to Defeat Solid Tumors breakthrough-in-oncology-combining-radiopharmaceuticals-and-car-t-cell-therapy-to-defeat-solid-tumors

Breakthrough in Oncology: Combining Radiopharmaceuticals and CAR T-Cell Therapy to Defeat Solid Tumors

Ali Ikhwan July 24, 2026

In a significant stride toward overcoming one of the most stubborn hurdles in modern oncology, a team...

FDA Approves Subcutaneous Isatuximab-irfc: A Paradigm Shift in Multiple Myeloma Care fda-approves-subcutaneous-isatuximab-irfc-a-paradigm-shift-in-multiple-myeloma-care

FDA Approves Subcutaneous Isatuximab-irfc: A Paradigm Shift in Multiple Myeloma Care

Asro July 23, 2026

The landscape of multiple myeloma (MM) treatment has undergone a significant evolution following the U.S. Food and...

Precision Oncology: AI-Driven Breakthrough Revolutionizes Brain Tumor Drug Delivery precision-oncology-ai-driven-breakthrough-revolutionizes-brain-tumor-drug-delivery

Precision Oncology: AI-Driven Breakthrough Revolutionizes Brain Tumor Drug Delivery

Lina Irawan July 23, 2026

In the high-stakes field of neurointerventional oncology, the challenge of treating malignant brain tumors has long been...

The New Frontier of Multiple Myeloma: Navigating the BCMA Revolution and Post-CAR T-Cell Relapse the-new-frontier-of-multiple-myeloma-navigating-the-bcma-revolution-and-post-car-t-cell-relapse

The New Frontier of Multiple Myeloma: Navigating the BCMA Revolution and Post-CAR T-Cell Relapse

Pevita Pearce July 23, 2026

The landscape of multiple myeloma treatment has shifted from a paradigm of chronic disease management to one...

The Postpartum Window: Decoding the Biological Risks of Breast Cancer After Childbirth the-postpartum-window-decoding-the-biological-risks-of-breast-cancer-after-childbirth

The Postpartum Window: Decoding the Biological Risks of Breast Cancer After Childbirth

Nana July 22, 2026

For years, the medical community has grappled with an unsettling trend: a rising incidence of breast cancer...

A New Frontier in Oncology: Experimental Vaccine Shows Promise in Intercepting Pancreatic Cancer a-new-frontier-in-oncology-experimental-vaccine-shows-promise-in-intercepting-pancreatic-cancer

A New Frontier in Oncology: Experimental Vaccine Shows Promise in Intercepting Pancreatic Cancer

Pevita Pearce July 22, 2026

In a groundbreaking development for oncology, researchers have unveiled results from a phase I clinical trial that...

Precision in Oncology: i31-SLNB Test Outperforms Traditional Nomograms in Melanoma Management precision-in-oncology-i31-slnb-test-outperforms-traditional-nomograms-in-melanoma-management

Precision in Oncology: i31-SLNB Test Outperforms Traditional Nomograms in Melanoma Management

Raul Delapena Setiawan July 21, 2026

In the evolving landscape of dermatological oncology, the quest to balance diagnostic precision with patient safety remains...

A Decade of Hope: Landmark Penn Medicine Study Suggests Potential Cures for Lymphoma via CAR T Cell Therapy a-decade-of-hope-landmark-penn-medicine-study-suggests-potential-cures-for-lymphoma-via-car-t-cell-therapy

A Decade of Hope: Landmark Penn Medicine Study Suggests Potential Cures for Lymphoma via CAR T Cell Therapy

Azzam Bilal Chamdy July 21, 2026

In a milestone for modern oncology, long-term follow-up data from one of the earliest clinical trials of...

The Invisible Barrier: Addressing the Dual Crisis of Immigration Status and Cancer Care the-invisible-barrier-addressing-the-dual-crisis-of-immigration-status-and-cancer-care-1

The Invisible Barrier: Addressing the Dual Crisis of Immigration Status and Cancer Care

Jia Lissa July 21, 2026

In the complex landscape of oncology, medical expertise is only one half of the equation. For the...

Redefining High-Risk Biochemically Recurrent Prostate Cancer: Insights from the EMBARK Trial redefining-high-risk-biochemically-recurrent-prostate-cancer-insights-from-the-embark-trial

Redefining High-Risk Biochemically Recurrent Prostate Cancer: Insights from the EMBARK Trial

Evan Lee Salim July 20, 2026

The management of high-risk biochemically recurrent (BCR) prostate cancer—a condition characterized by rising prostate-specific antigen (PSA) levels...

Clinical Oncology Education

Breakthrough in Oncology: Combining Radiopharmaceuticals and CAR T-Cell Therapy to Defeat Solid Tumors

FDA Approves Subcutaneous Isatuximab-irfc: A Paradigm Shift in Multiple Myeloma Care

Precision Oncology: AI-Driven Breakthrough Revolutionizes Brain Tumor Drug Delivery

The New Frontier of Multiple Myeloma: Navigating the BCMA Revolution and Post-CAR T-Cell Relapse

The Postpartum Window: Decoding the Biological Risks of Breast Cancer After Childbirth

A New Frontier in Oncology: Experimental Vaccine Shows Promise in Intercepting Pancreatic Cancer

Precision in Oncology: i31-SLNB Test Outperforms Traditional Nomograms in Melanoma Management

A Decade of Hope: Landmark Penn Medicine Study Suggests Potential Cures for Lymphoma via CAR T Cell Therapy

The Invisible Barrier: Addressing the Dual Crisis of Immigration Status and Cancer Care

Redefining High-Risk Biochemically Recurrent Prostate Cancer: Insights from the EMBARK Trial

You may have missed

The Dismantling of U.S. Global Health: A Post-Mortem on the Restructuring of Maternal and Child Health Initiatives

The Yoga Mat as a Social Conduit: How One Prop Transforms Urban Isolation into Community

Groundbreaking Study Uncovers Specific Link Between Linoleic Acid and Aggressive Breast Cancer Subtype, Paving Way for New Strategies

From Diabetes to MASH: The Evolving Science and Supply Chain Behind the GLP-1 Revolution